RxDoctor Payments Data

Amanda Bibbs

Family · Tulsa, OKNPI 1609396944

Payments from drug & device makers

$2,973in general payments, 2019–2025

Across 80 payments — averaging $37.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$735
  • AstraZeneca$575
  • GSK$458
  • Johnson & Johnson$375
  • AbbVie$338
  • UCB, Inc.$223
  • plus $268 from 4 others

What the payments were for

  • Food & beverage$2,973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,973 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$266,251
Medicare patients
203
Services billed
18,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept112$858,134
Humira(Cf) PenAdalimumab51$522,639
OtezlaApremilast53$268,922
Xeljanz XrTofacitinib Citrate30$168,239
Humira(Cf)Adalimumab12$166,983
SimponiGolimumab20$138,542
BenlystaBelimumab38$130,021
Orencia ClickjectAbatacept14$89,256
OrenciaAbatacept/Maltose13$36,162
Hydroxychloroquine Sulfate686$32,765
Leflunomide165$12,980
Sulfasalazine DrSulfasalazine197$6,868
Azathioprine227$6,004
MethotrexateMethotrexate Sodium160$5,559
Celecoxib98$3,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$735$268,92253 claims
AbbVieHumira(Cf)$338$166,98312 claims
Johnson & JohnsonSimponi$375$138,54220 claims
GSKBenlysta$458$130,02138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,026 family providers in Oklahoma.

Other family in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →